Michael Robertson

11.5k citations

137 papers · 6.4k · 4 hit papers · h-index 38

Impact in

Virology top 0.2%
- HIV Research and Treatment
Hepatology top 0.2%
- Hepatitis C virus research

Papers in

Hepatology 62
- Hepatitis C virus research 62
Epidemiology 47
- Hepatitis B Virus Studies 15
- Cervical Cancer and HPV Research 13
- Liver Disease Diagnosis and Treatment 12

Co-authors: Danilo R. Casimiro (15 shared papers)Devan V. Mehrotra (14 shared papers)Janice Wahl (42 shared papers)Susan Buchbinder (6 shared papers)Lawrence Corey (7 shared papers)M. Juliana McElrath (5 shared papers)Eliav Barr (25 shared papers)Peter B. Gilbert (7 shared papers)
Journals: Journal of Hepatology (20 papers)The Journal of Infectious Diseases (11 papers)Journal of Viral Hepatitis (8 papers)International Journal of Cancer (6 papers)AIDS Research and Human Retroviruses (5 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Michael Robertson

137 papers receiving 6.3k citations

Michael Robertson's Hit Papers

align trajectories log scale

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection 2015 · 388 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Annals of Internal Medicine
2015 The Lancet
2008 The Lancet
2008 The Lancet

Peers

Countries citing papers authored by Michael Robertson

Since Specialization

Citations

This map shows the geographic impact of Michael Robertson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Robertson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Robertson more than expected).

Fields of papers citing papers by Michael Robertson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Robertson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Robertson. The network helps show where Michael Robertson may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Robertson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Robertson Line = papers co-authored together Michael Robertson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 137 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial The Lancet ·Susan Buchbinder, Devan V. Mehrotra, Ann Duerr, Daniel W. Fitzgerald, Robin Mogg, David Li, Peter B. Gilbert, Javier R. Lama, Michael Marmor, Carlos del Rı́o, M. Juliana McElrath, Danilo R. Casimiro, Keith Gottesdiener, Jeffrey Chodakewitz, Lawrence Corey, Michael Robertson Hit paper breakdown →	2008	1221
2	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis The Lancet ·M. Juliana McElrath, Stephen C. De Rosa, Zoe Moodie, Sheri Dubey, Lisa Kierstead, Holly Janes, Olivier Defawe, Donald K. Carter, John Hural, Rama Akondy, Susan Buchbinder, Michael Robertson, Devan V. Mehrotra, Steven G. Self, Lawrence Corey, John W. Shiver, Danilo R. Casimiro Hit paper breakdown →	2008	519
3	Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study The Lancet ·David Roth, David R. Nelson, Annette Bruchfeld, AnnMarie Liapakis, Marcelo Silva, Howard Monsour, Paul Martin, Stanislas Pol, María‐Carlota Londoño, Tarek Hassanein, Philippe J. Zamor, Eli Zuckerman, Shuyan Wan, Beth Jackson, Bach-Yen Nguyen, Michael Robertson, Eliav Barr, Janice Wahl, Wayne Greaves Hit paper breakdown →	2015	478
4	Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection Annals of Internal Medicine ·Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy, Paul J. Pockros, Ziv Ben Ari, Yue Zhao, Deborah D. Brown, Shuyan Wan, Mark J. DiNubile, Bach‐Yen Nguyen, Michael Robertson, Janice Wahl, Eliav Barr, Joan R. Butterton Hit paper breakdown →	2015	388
5	Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial The Lancet HIV ·Jürgen K. Rockstroh, Mark Nelson, Christine Katlama, Jay Lalezari, Josep Mallolas, Mark Bloch, Gail Matthews, Michael S. Saag, Philippe J. Zamor, Chloe Orkin, Jacqueline Gress, Stephanie O. Klopfer, Melissa Shaughnessy, Janice Wahl, Bach-Yen Nguyen, Eliav Barr, Heather Platt, Michael Robertson, Mark Sulkowski	2015	219
6	Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study) The Journal of Infectious Diseases ·Ann Duerr, Yunda Huang, Susan Buchbinder, Robert W. Coombs, Jorge Sánchez, Carlos del Rı́o, Martín Casapía, Solano Kaluangila Andrelino Santiago, Peter B. Gilbert, Lawrence Corey, Michael Robertson, (unknown)	2012	146
7	A population‐based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination International Journal of Cancer ·Cosette M. Wheeler, William C. Hunt, Jack Cuzick, Erika Langsfeld, Amanda Pearse, George D. Montoya, Michael Robertson, Catherine A. Shearman, Philip E. Castle	2012	138
8	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection Gastroenterology ·Paul Y. Kwo, Edward Gane, Cheng‐Yuan Peng, Brian L. Pearlman, John M. Vierling, Lawrence Serfaty, Marı́a Buti, Stephen D. Shafran, Paul Stryszak, Lin Li, Jacqueline Gress, Stuart Black, Frank J. Dutko, Michael Robertson, Janice Wahl, Lisa Lupinacci, Eliav Barr, Barbara Haber	2016	125
9	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent Journal of Hepatology ·Xavier Forns, Stuart C. Gordon, Eli Zuckerman, Eric Lawitz, José Luís Calleja, Harald Hofer, Christopher L. Gilbert, John Palcza, A Howe, Mark J. DiNubile, Michael Robertson, Janice Wahl, Eliav Barr, Marı́a Buti	2015	110
10	Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans Nature Medicine ·Kara L. O’Brien, Jinyan Liu, Sharon L King, Ying-Hua Sun, Jörn E. Schmitz, Michelle A. Lifton, Natalie A. Hutnick, Michael R. Betts, Sheri Dubey, Jaap Goudsmit, John W. Shiver, Michael Robertson, Danilo R. Casimiro, Dan H. Barouch	2009	110
11	Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine Journal of Clinical Investigation ·Nicole Frahm, Allan C. deCamp, David P. Friedrich, Donald K. Carter, Olivier Defawe, James G. Kublin, Danilo R. Casimiro, Ann Duerr, Michael Robertson, Susan Buchbinder, Yunda Huang, Gregory A. Spies, Stephen C. De Rosa, M. Juliana McElrath	2011	109
12	Production of monoclonal antibodies reactive with a denatured form of the friend murine leukemia virus gp70 envelope protein: Use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting Journal of Virological Methods ·Michael Robertson, Masaaki Miyazawa, Shiro Mori, Byron Caughey, Leonard H. Evans, Stanley F. Hayes, Bruce Chesebro	1991	106
13	Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era JAMA Oncology ·Vicki B. Benard, Philip E. Castle, Steven Jenison, William C. Hunt, Jane J. Kim, Jack Cuzick, Ji‐Hyun Lee, Ruofei Du, Michael Robertson, Scott Norville, Cosette M. Wheeler	2016	85
14	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study The Lancet Infectious Diseases ·Glenda Gray, Zoe Moodie, Barbara Metch, Peter B. Gilbert, Linda‐Gail Bekker, Gavin Churchyard, Maphoshane Nchabeleng, Koleka Mlisana, Fatima Laher, Surita Roux, Kathryn Mngadi, Craig Innes, Matsontso Mathebula, Mary Allen, Margaret J McElrath, Michael Robertson, James G. Kublin, Lawrence Corey	2014	83
15	AIDS Clinical Trials Group 5197: A Placebo‐Controlled Trial of Immunization of HIV‐1–Infected Persons with a Replication‐Deficient Adenovirus Type 5 Vaccine Expressing the HIV‐1 Core Protein The Journal of Infectious Diseases ·Robert T. Schooley, John Spritzler, Hongying Wang, Michael M. Lederman, Diane V. Havlir, Daniel R. Kuritzkes, Richard B. Pollard, Cathy Battaglia, Michael Robertson, Devan V. Mehrotra, Danilo R. Casimiro, (unknown), Barbara Schock	2010	77
16	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1. Clinical Infectious Diseases ·Marı́a Buti, Stuart C. Gordon, Eli Zuckerman, Eric Lawitz, José Luís Calleja, Harald Hofer, Christopher L. Gilbert, John Palcza, Anita Y. M. Howe, Mark J. DiNubile, Michael Robertson, Janice Wahl, Eliav Barr, Xavier Forns	2015	77
17	Performance, biochemical, and endocrine changes during a competitive football game Medicine & Science in Sports & Exercise ·Jay R. Hoffman, Carl M. Maresh, Robert U. Newton, Martyn R. Rubin, Duncan N. French, Jeff S. Volek, Jason W Sutherland, Michael Robertson, A L. G mez, Nicholas A. Ratamess, Jie Kang, William J. Kraemer	2002	76
18	Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia Cancer Epidemiology Biomarkers & Prevention ·Rachael Adcock, Jack Cuzick, William C. Hunt, Ruth McDonald, Cosette M. Wheeler, Nancy E. Joste, Walter Kinney, Michael Robertson, Alan G. Waxman, Steven Jenison, Julia C. Gage, Philip E. Castle, Vicki B. Benard, Debbie Saslow, Jane J. Kim, Mark H. Stoler, Giovanna Rossi Pressley, Kevin English	2019	72
19	Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cells Nature Medicine ·Natalie A. Hutnick, Diane G. Carnathan, Sheri Dubey, George Makedonas, (unknown), Lisa Kierstead, Sarah J. Ratcliffe, Michael Robertson, Danilo R. Casimiro, Hildegund C.J. Ertl, Michael R. Betts	2009	72
20	Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease Antimicrobial Agents and Chemotherapy ·Johan Maertens, Oliver A. Cornely, Andrew J. Ullmann, Werner Heinz, Gopal Krishna, Hernando Patino, Maria Caceres, Nicholas A. Kartsonis, Hetty Waskin, Michael Robertson	2014	70

About Michael Robertson

Michael Robertson is a scholar working on Hepatology, Epidemiology, Infectious Diseases, Virology and Immunology, having authored 137 papers that have together received 6.4k indexed citations. Recurring topics across this work include Hepatitis C virus research (62 papers), HIV Research and Treatment (32 papers), HIV/AIDS drug development and treatment (30 papers), Hepatitis B Virus Studies (15 papers), Cervical Cancer and HPV Research (13 papers), Liver Disease Diagnosis and Treatment (12 papers), Virus-based gene therapy research (11 papers) and Chronic Lymphocytic Leukemia Research (9 papers). The work is most often cited by research in Virology (1.9k citations), Hepatology (2.2k citations), Infectious Diseases (1.6k citations), Epidemiology (2.5k citations) and Immunology (1.3k citations). Michael Robertson has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Danilo R. Casimiro, Devan V. Mehrotra, Janice Wahl, Susan Buchbinder, Lawrence Corey, M. Juliana McElrath, Eliav Barr, Peter B. Gilbert, Ann Duerr and Carlos del Rı́o. Their work appears in journals such as Journal of Hepatology, The Journal of Infectious Diseases, Journal of Viral Hepatitis, International Journal of Cancer and AIDS Research and Human Retroviruses.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Michael Robertson

Impact in

Papers in i

In The Last Decade

Michael Robertson

Michael Robertson's Hit Papers

Peers

Countries citing papers authored by Michael Robertson

Fields of papers citing papers by Michael Robertson

All Works

About Michael Robertson

Explore authors with similar magnitude of impact

Papers in